Introduction
============

The introduction of effective antiretroviral therapy has resulted in a marked reduction in AIDS-related mortality worldwide. Patterns of morbidity and mortality have shifted from AIDS-related opportunistic infections to age-related comorbidities; moreover, it is now recognized that people living with HIV (PLHIV) are at increased risk of developing cardiovascular disease \[[@ref1],[@ref2]\]. This increased risk is likely to be of multifactorial origin \[[@ref3]\]: the disease and its treatment. Moreover, PLHIV are predisposed to engage in unhealthy behaviors \[[@ref1],[@ref2]\].

Tobacco use is the single most common cause of preventable death worldwide and an important modifiable risk factor for several chronic conditions, including coronary heart diseases, chronic obstructive pulmonary diseases, and certain cancers \[[@ref4]\]. About 15% of the world's population smoked tobacco in 2015 \[[@ref5]\]. However, prevalence estimates of tobacco use in vulnerable populations are much higher: 32% among people with mental health disorders \[[@ref6]\], 73% among homeless people \[[@ref7]\], 77% among substance abusers \[[@ref8]\], and 84% among prisoners \[[@ref9]\]. Of note, the prevalence of smoking in PLHIV ranges between 50% and 70% \[[@ref10]\], and like other vulnerable groups, success rates of quitting attempts and sustained abstinence are much lower than in the general population \[[@ref11]\]. Smoking for stress relief, inadequate support from health service providers, and high smoking acceptance rates among communities of PLHIV are among the perceived barriers to abstinence in this high-risk group, and these considerably differ from self-reported barriers in apparently healthy populations without known chronic conditions \[[@ref11]\]. For these reasons, intervention strategies for smoking cessation in the general population may not be as effective in HIV-positive populations. Although there have been several reports on the effectiveness of smoking cessation interventions among PLHIV \[[@ref12]\], there are still questions left unanswered, notably about the mode of intervention delivery and its impact on smoking cessation. Short message service (SMS) text messages and other phone-based strategies have the potential to be more cost effective in service delivery than face-to-face contact, but it has been hypothesized that such mobile health (mHealth) strategies might be less effective or no different in terms of achieving smoking abstinence \[[@ref12]\]. mHealth services provide unique opportunities for delivering smoking cessation interventions to large number of people at a low cost. However, there is no systematic evidence to substantiate this hypothesis. Therefore, we first sought to review all existing literature investigating mHealth and face-to-face interventions for smoking cessation among PLHIV. Second, we examined whether the required amount of information has been reached to confidently conclude that mHealth is more effective than no mHealth and that future trials need not examine this question any longer.

Methods
=======

Information Sources and Search Strategy
---------------------------------------

We conducted searches on the following major databases: Embase, Medical Literature Analysis and Retrieval System Online, the Cochrane Library Central Register of Controlled Trials, the ClinicalTrials.gov registry, and cross-references of relevant articles for randomized controlled trials (RCTs) investigating the effectiveness of smoking cessation interventions among HIV-positive smokers and published until up to May 2018. [Multimedia Appendix 1](#app1){ref-type="supplementary-material"} shows the database search strategy, including the search term combinations used.

Selection Criteria
------------------

We evaluated each identified study against the following predetermined selection criteria: *Types of population* (PLHIV); *types of intervention and comparator* (face-to-face counseling, mHealth-delivered intervention, or no intervention country group); *types of outcome* (smoking abstinence); and *study design* (RCTs).

Selection of Studies
--------------------

Two authors (CUN and MA) screened the titles and abstracts of all the potential studies we identified as a result of the search and coded them as "retrieve" (eligible or potentially eligible or unclear) or as "do not retrieve." Any disagreements were arbitrated by a third author (OAU). Subsequently, CUN and MA assessed the full-text study reports to confirm their eligibility for inclusion while noting the reasons for excluding studies considered ineligible for the meta-analysis. Again, any disagreements were resolved following discussions with OAU.

Data Extraction
---------------

CUN and MA extracted demographic and clinical data from the included studies where available. Data on trial design, sample size, mean age, proportion of women, average daily number of cigarettes, interventions, outcomes, and follow-up durations were extracted. Any disagreements were resolved following discussions with OAU.

Outcome Measures
----------------

The main outcome was short-term smoking abstinence, which has been defined as abstinence of at least 4 weeks duration, but less than 6 months after the intervention was initiated \[[@ref12]\]. The secondary outcome was smoking abstinence of at least 6 months duration (long-term abstinence) \[[@ref13]\].

Risk of Bias Assessment
-----------------------

CUN and MA judged the risk of bias in each included study using the Cochrane risk of bias assessment tool, which includes the following domains: randomization sequence generation (selection bias); allocation concealment (selection bias); blinding of participants, providers, (performance bias) and outcome assessors (detection bias); completeness of outcome data (attrition bias); and selective outcome reporting (reporting bias). Each RCT was classified as having "high," "low," or "unclear" risk of bias in each domain \[[@ref14]\]. OAU resolved any differences in the assessments.

Statistical Analysis
--------------------

We adopted an adjusted indirect comparison meta-analysis \[[@ref15]-[@ref18]\], a logical extension of standard meta-analysis to infer relative effectiveness of mHealth-delivered versus face-to-face interventions when the direct "head-to-head" evidence is lacking, that is, not directly addressed within any of the included trials. To illustrate this, in a situation where we have 3 treatments A (mHealth), B (face-to-face), and C (no intervention control), A and C have been compared in RCTs; B and C have been compared in other RCTs; and A and B had not been directly compared. The approach enabled the indirect comparisons (eg, A vs B) constructed from 2 trials that have one treatment in common to be incorporated (eg, A vs C and B vs C; [Figure 1](#figure1){ref-type="fig"}). Using Bucher adjusted indirect comparison method, the treatment effect for *T*~*AB*~ can be calculated by using the following equation:
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All data were analyzed using R package "stats" (version 3.2.2). As part of the primary analysis, subgroup analysis was conducted based on the intensity and duration of follow-up period. Analysis was performed separately for short-term (4 weeks to \<6 months) and long-term (≥6 months) smoking abstinence. We also quantified heterogeneity by computing the *I*^2^ statistic; a value greater than 50% implied that the treatment estimates were considerably heterogeneous across the included studies. The pooled treatment estimates were reported using RRs and 95% CIs.

We examined the reliability and conclusiveness of the available evidence using trial sequential analyses (TSA) \[[@ref19]-[@ref21]\]. The sample size required for a reliable and conclusive meta-analysis is at least as large as that of a single optimally powered RCT. Therefore, we calculated the sample size (ie, the heterogeneity-corrected optimal information size) required to detect or reject a minimal 25% relative risk reduction intervention effect. We then used the heterogeneity-corrected optimal information size to help construct Lan-DeMets sequential monitoring boundaries for our cumulative meta-analyses \[[@ref22]\], analogous to interim monitoring in an RCT, to determine when sufficient evidence had been accrued ([Figure 2](#figure2){ref-type="fig"}): Significant (*P*\<.05) meta-analysis included potentially spurious evidence of effect, that is, the cumulative Z-curve did not cross the monitoring boundaries (curve A), or firm evidence of effect, that is, the cumulative Z-curve crossed the monitoring boundaries (curve B). Nonsignificant (*P* ≥.05) meta-analysis included absence of evidence, that is, the meta-analysis included less patients than the required information size (curve C), or lack of effect, that is, the meta-analysis included more patients than the required information size (curve D). We conducted TSA using TSA version 0.937 with an intention to maintain an overall 5% risk of a type I error and 20% risk of a type II error (power of 80%).

![Adjusted indirect comparison network meta-analysis framework. A: mhealth delivered; B: face to face; C: standard of care.](mhealth_v7i1e203_fig1){#figure1}

![Trial sequential analysis.](mhealth_v7i1e203_fig2){#figure2}

Results
=======

Study Selection and Characteristics of Included Studies
-------------------------------------------------------

The study selection process is illustrated in [Figure 3](#figure3){ref-type="fig"}. The search strategy yielded 308 records, and upon screening abstracts and duplicate records, we identified 23 potentially eligible studies. We excluded 13 additional studies for the following reasons: the outcome was not abstinence (4 studies), no control group existed (4 studies), follow-up was less than 4 weeks (1 study), the study was quasi-experimental (1 study), face-to-face or mHealth interventions were not specified (1 study), a zero smoking abstinence rate was found in both the intervention and control groups, a computational error was identified (1 study), and participants in the intervention arm received either mHealth or face-to-face interventions but not both (1 study). Hence, 10 RCTs met the inclusion criteria and were included in the analysis \[[@ref23]-[@ref32]\].

The 10 included studies comprised a total of 1772 participants, all of whom were current smokers living with HIV. All studies were from a high-income country, that is, the United States ([Table 1](#table1){ref-type="table"}). On average, each participant at baseline smoked about 16 cigarettes daily (range 11-20). The average age of the study population was 45 years (range 42-50), and women comprised about 37% (range 8%-100%). Smoking cessation strategies were administered face-to-face in 7 studies \[[@ref23]-[@ref27],[@ref29],[@ref30]\], and sustained smoking abstinence estimates were reported in 4 studies \[[@ref23],[@ref30]-[@ref32]\]. The intensity and maximum follow-up period ranged from 4 weeks to as much 52 weeks. The number of counseling also varied across the studies, from 1 session to 11 sessions.

Risk of Bias in Included Studies
--------------------------------

Among the 10 included studies, 6 reported the use of computer-generated lists of random numbers for randomization, whereas the other 4 studies did not describe the random sequence generation process. Allocation concealment was not described in any study; therefore, the risks of selection bias were unclear. Blinding of the participants and investigators was not described in 9 of the 10 studies, leaving 1 study in which investigators facilitated counseling sessions, which was thus judged to have a high risk of performance bias. Outcomes assessors were masked to the intervention in 2 studies, whereas the other 8 studies were assessed to have unclear risks of detection bias. Attrition bias was low in 7 studies, and reporting bias high or unclear in 5 studies ([Figure 4](#figure4){ref-type="fig"}).

Short-Term Smoking Cessation (4 Weeks to \<6 Months)
----------------------------------------------------

[Figure 5](#figure5){ref-type="fig"} displays a caterpillar plot of the relative RRs and 95% CIs of efficacy for all possible pairwise comparisons of the different treatment strategies. For short-term smoking cessation (ie, ≥4 weeks of smoking abstinence within 6 months of the intervention), 7 trials compared face-to-face intervention versus no intervention control group, and 4 compared mHealth-delivered interventions versus no intervention control group (n=1870). Participants randomized to SMS-delivered interventions were 2.81 times more likely to have stopped smoking compared to those who received standard care (RR 2.81, 95% CI 1.44-5.49). In addition, PLHIV who received mHealth-delivered interventions were twice as likely to have stopped smoking compared to those who received face-to-face interventions (RR 2.31, 95% 1.13-4.72). On average, face-to-face interventions were no more effective than no intervention in increasing short-term smoking cessation (RR 1.22, 95% CI 0.94-1.58). The measure of inconsistency between studies (*I*^2^) was 6.3%, suggesting that the included studies were not statistically heterogeneous.

![Study selection flow diagram. SMS: short message service.](mhealth_v7i1e203_fig3){#figure3}

###### 

Characteristics of the included studies.

  Study                                Sample size   Average age, years   Women (%)   Average daily number of cigarettes   Intervention                                                                                                                      Outcome                                     Follow-up durations
  ------------------------------------ ------------- -------------------- ----------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ---------------------------
  Humfleet 2015 \[[@ref23]\]           209           45                   18          19.8                                 1 face-to-face CBT^b^ session and 6 face-to-face CBT sessions                                                                     Sustained smoking abstinence                12, 24, 26, and 52 weeks
  Ingersoll 2009 \[[@ref24]\]          40            42                   45          17.3                                 1 face-to-face counseling session                                                                                                 7-day point prevalence smoking abstinence   4 and 12 weeks
  Lloyd-Richardson 2009 \[[@ref25]\]   444           42                   37          18.2                                 4 face-to-face counseling sessions                                                                                                7-day point prevalence smoking abstinence   2, 4, and 6 months
  Manuel 2013 \[[@ref26]\]             30            49                   100         16.1                                 1 face-to-face counseling session                                                                                                 7-day point prevalence smoking abstinence   4 weeks
  Moadel 2012 \[[@ref27]\]             145           49                   51          12.0                                 8 face-to-face counseling sessions                                                                                                7-day point prevalence smoking abstinence   42 and 132 days
  Shelley 2015 \[[@ref28]\]            158           50                   16          15.0                                 Twice daily short message service text messages and twice daily short message service text messages+7 phone counseling sessions   7-day point prevalence smoking abstinence   1, 4, 8, 12, and 24 weeks
  Shuter 2014 \[[@ref29]\]             138           46                   40          10.9                                 8 face-to-face CBT sessions                                                                                                       7-day point prevalence smoking abstinence   6 weeks, 3 months
  Tucker 2017 \[[@ref30]\]             40            42.9                 8           13.0                                 Face-to-face counseling                                                                                                           Sustained smoking abstinence                3 months
  Vidrine 2006 \[[@ref31]\]            94            43                   22          20.1                                 8 phone counseling sessions                                                                                                       Sustained smoking abstinence                3 months
  Vidrine 2012 \[[@ref32]\]            474           45                   30          19.2                                 11 phone counseling sessions                                                                                                      Sustained smoking abstinence                3, 6, and 12 months

^a^RCT: randomized controlled trial.

^b^CBT: cognitive behavioral therapy.

![Risk of bias in included studies.](mhealth_v7i1e203_fig4){#figure4}

![Pairwise comparisons of all interventions, short-term effect. RR: risk ratio; SMS: short message service; SoC: standard of care, no intervention control.](mhealth_v7i1e203_fig5){#figure5}

![Trial sequential analysis for mHealth for smoking cessation in people living with HIV, short-term effect. mHealth: mobile health.](mhealth_v7i1e203_fig6){#figure6}

Our calculations indicated that the optimal information size needed to reliably detect a plausible treatment effect for short-term smoking cessation is 4797 participants ([Figure 6](#figure6){ref-type="fig"}). However, only 15.16% (726/4787) of the participants of the required information size were accrued. More so, the sequential monitoring boundary has not been crossed, indicating that the cumulative evidence is unreliable and inconclusive ([Figure 6](#figure6){ref-type="fig"}).

Long-Term Smoking Cessation (≥6 Months)
---------------------------------------

For long-term smoking cessation, that is, abstinence ≥6 months, 3 trials compared face-to-face intervention versus no intervention control group and 2 compared mHealth-delivered interventions versus no intervention control group (n=1546). There was no significant difference in smoking cessation rates between PLHIV randomized to mHealth-delivered interventions and those in the no intervention control group (RR 0.67, 95% CI 0.27-1.67). Similarly, there was no significant difference in smoking cessation rates between face-to-face interventions and no intervention control groups (RR 1.02, 95% CI 0.68-1.53). In addition, adjusted indirect treatment comparison between face-to-face and mHealth interventions revealed no significant difference (RR 0.65, 95% CI 0.29-1.47; [Figure 7](#figure7){ref-type="fig"}). The measure of inconsistency between the included studies (*I*^2^) was 0%, suggesting no evidence that the included studies were statistically heterogeneous.

![Pairwise comparisons of all interventions, long-term effect. RR: risk ratio; SMS: short message service; SoC: standard of care, no intervention control.](mhealth_v7i1e203_fig7){#figure7}

![Trial sequential analysis for mHealth for smoking cessation in people living with HIV, long-term effect. mHealth: mobile health.](mhealth_v7i1e203_fig8){#figure8}

Our calculations indicated that the optimal information size needed to reliably detect a plausible treatment effect for long-term smoking cessation was 11,364 participants ([Figure 8](#figure8){ref-type="fig"}). However, only 5.56% (632/11,364) participants of the required information size were accrued in the pooled analysis. The sequential monitoring boundary has also not been crossed, indicating that the cumulative evidence is unreliable and inconclusive ([Figure 8](#figure8){ref-type="fig"}).

In [Figure 8](#figure8){ref-type="fig"}, dashed blue cumulative Z curves do not cross solid black trial sequential monitoring boundaries for benefit and horizontal red lines illustrate the traditional level of statistical significance (*P*=.05).

Discussion
==========

Principal Findings
------------------

The results suggest that mHealth interventions for smoking cessation in PLHIV leads to better short-term improvement in smoking cessation rates than face-to-face interventions. However, from 6 months after the intervention and onward, there is no evidence of any effect regardless of the mode of intervention delivery. Our findings are broadly consistent with a previous meta-analysis of studies conducted in the general population, which reported a higher pooled smoking abstinence rate associated with SMS text messaging for 3 months compared to SMS text messaging for 6 months \[[@ref33]\]. It is important to note that the absence of evidence is not evidence of absence of long-term effects of mHealth-delivered interventions. The lack of significant differences in long-term abstinence, however, may be due to the small number of studies contributing to this indirect evidence network, and as such, the evidence is inconclusive. Accurate understanding of the strength of the evidence for mHealth requires a systematic, comprehensive, and unbiased accumulation of the available evidence and methods adopted from formal interim monitoring boundaries applied to cumulative meta-analysis. The results of our TSA showed that the evidence that mHealth increases smoking cessation rates in the short term is encouraging but may be unreliable to make conclusive inferences.

Given the crucial need for the prevention of cardiovascular disease risk in PLHIV, there is a need for future pragmatic trials comparing mHealth and face-to-face intervention, especially in resource-limited settings that bear the highest burden of HIV and where smoking is now a bigger problem \[[@ref2],[@ref34]\]. Furthermore, low-income settings are now experiencing an epidemiological transition from infectious diseases to chronic diseases \[[@ref2]\] as a result of dramatic changes in diet and lifestyle. The epidemiological transition in resource-limited settings is happening over a shorter time frame than that experienced historically by high-income countries \[[@ref34]\]. In addition, there is a need to identify mHealth-delivered interventions that are most beneficial for PLHIV. We should also investigate innovative specific features of mHealth interventions that can achieve long-term effects, for example, by varying the mode of delivery (weekly SMS text messaging) or by personalized and more tailored SMS text messages.

Limitations
-----------

The limitations in our study warrant consideration. First, the included studies were conducted in a high-income setting, which potentially limits generalization of the results to low- and middle-income settings in which the burden of HIV and tobacco-related illnesses and deaths are currently most severe \[[@ref5]\]. Nonetheless, our findings may be generalizable to other vulnerable groups in high-income countries. Second, the intervention arms in the included studies all comprised multicomponent strategies, which may have influenced our results; however, tests for heterogeneity revealed that the studies included in our analyses were in fact homogeneous. Third, we could not compare mHealth or face-to-face interventions with strategies that entailed a combination of both interventions because none of the included studies allowed this dual treatment in the intervention arm. Wewers et al \[[@ref35]\] examined mHealth and face-to-face interventions in their study; however, we considered this study ineligible because the participants received either mHealth or face-to-face interventions and not both and because the numbers were not specified. Furthermore, with only 10 studies considered eligible for our review, we could not perform meta-regression analyses to explore potential effect-modifiers such as age, sex, coexisting substance abuse, and average number of cigarettes smoked daily at baseline. In spite of these limitations, we present novel systematic evidence evaluating the preferred mode of contact to be employed for improving smoking abstinence among PLHIV.

Conclusion
----------

Compared to face-to-face interventions, mHealth-delivered interventions can boost smoking cessation rates, at least in the short term, among PLHIV with higher smoking prevalence rates than the general population. However, it remains unclear how long the effects of such interventions last. Future research should focus on strategies for sustaining the treatment effect in the long term and move beyond high-income settings.
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